Antisense Therapeutics to Present at MS Conference

Antisense Therapeutics Ltd (ASX:ANP) has recently reported on data showing ATL1102 significantly reduces the number of active multiple sclerosis (MS) brain lesions that convert to ‘Black Holes’ is to be presented at the 7th Joint ECTRIMSACTRIMS Meeting in Paris, France 25-28 October 2017.

KEY TAKEAWAYS: 

• The world’s largest international conference devoted to basic and clinical research in MS.

Professor Barkhof, said “the ATL1102 ‘Black Holes’ data is most compelling which is reflected in its selection for late-breaker poster presentation”.

Importantly, the positive effect of ATL1102 suggests that along with its action in reducing the number of new inflammatory brain lesions, ATL1102 may also be neuroprotective by reducing damage to axons in the lesions and thereby slow the MS disease progression.

Further information on the meeting can be found at https://www.ectrims-congress.eu/2017.html

Request Information